Radiopharm Theranostics Limited (RADX)

NASDAQ: RADX · Real-Time Price · USD

1.110

-0.040 (-3.48%)

At close: Oct 8, 2026, 4:00 PM EDT

1.000

-0.110 (-9.91%)

Pre-market: Oct 9, 2026, 5:17 AM EDT

Radiopharm Theranostics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Operating Revenue	2.77	3.63	0.3	0.29	-
Other Revenue	10.1	9.37	1.29	5.92	-
Revenue	12.87	13	1.59	6.21	-
Revenue Growth	-1.05%	716.81%	-74.37%	-	-
Cost of Revenue	47.2	31.11	21.61	19.53	7.49
Gross Profit	-34.34	-18.11	-20.02	-13.32	-7.49
Selling, General & Admin	16.22	14.64	13.04	12.23	7.64
Operating Expenses	18.62	16.53	15.68	15.27	12.44
Operating Income	-52.96	-34.64	-35.69	-28.59	-19.93
Interest Expense	-0.11	-0.07	-0.64	-0.09	-9.35
Interest & Investment Income	0.64	0.89	0.05	0.15	0.01
Currency Exchange Gain (Loss)	-0.66	0.14	0.09	-0.26	-1.11
EBT Excluding Unusual Items	-53.09	-33.68	-36.19	-28.79	-30.38
Gain (Loss) on Sale of Assets	-0.21	-	-1.69	-	-
Asset Writedown	-5.27	-	-1.48	-3.1	-
Other Unusual Items	1.67	-4.56	-8.49	-2.68	-
Pretax Income	-56.9	-38.24	-47.85	-34.57	-30.38
Income Tax Expense	0.05	0.1	0.1	0.04	0.04
Net Income	-56.95	-38.34	-47.95	-34.61	-30.42
Net Income to Common	-56.95	-38.34	-47.95	-34.61	-30.42
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	3,073	2,081	386	306	181
Shares Outstanding (Diluted)	3,073	2,081	386	306	181
Shares Change	47.68%	438.49%	26.36%	68.74%	-
EPS (Basic)	-0.02	-0.02	-0.12	-0.11	-0.17
EPS (Diluted)	-0.02	-0.02	-0.12	-0.11	-0.17
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Free Cash Flow	-52.78	-36.65	-22.98	-23.25	-9.91
Free Cash Flow Per Share	-0.02	-0.02	-0.06	-0.08	-0.06
Gross Margin	-266.89%	-139.27%	-	-214.52%	-
Operating Margin	-411.63%	-266.43%	-2242.42%	-460.41%	-
Profit Margin	-442.67%	-294.90%	-3012.25%	-557.36%	-
Free Cash Flow Margin	-410.28%	-281.85%	-1443.39%	-374.36%	-
EBITDA	-50.25	-32.05	-32.57	-25.29	-16.94
EBITDA Margin	-	-246.46%	-	-	-
D&A For EBITDA	2.71	2.6	3.13	3.3	2.98
EBIT	-52.96	-34.64	-35.69	-28.59	-19.93
EBIT Margin	-	-266.43%	-	-	-

SEC Filings: 10-K · 10-Q